Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects
作者： Omar Abdel-Rahman
DOI: 10.1016/J.CRITREVONC.2014.05.012
关键词:
摘要: The prognosis of advanced gastric cancer has been dreadful with the majority patients dying their disease within 1 year diagnosis. In stage several therapeutic options can be discussed, including molecular targeted agents, but biological predicting factors are lacking. A number targets have studied over last decade bringing to phase II studies; however very few agents moved into III clinical trials. VEGFR-2 inhibitor monoclonal antibody ramucirumab recently approved in progressing cancer. This article reviews basic science as well data VEGF signaling special emphasis on different targeting tested previously this disease.
croh-online.com 参考文章(49)
Fang Dong, Xiao-Qin Ha, Effect of endothelial progenitor cells in neovascularization and their application in tumor therapy Chinese Medical Journal. ,vol. 123, pp. 2454- 2460 ,(2010)
Jianping Fang, Ximei Chen, Changqing Yang, Xiaolei Wang, Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. International Journal of Clinical and Experimental Pathology. ,vol. 6, pp. 586- 597 ,(2013)
Gérald J. Prud’homme, Yelena Glinka, Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity Oncotarget. ,vol. 3, pp. 921- 939 ,(2012) , 10.18632/ONCOTARGET.626
Daniel Cejka, Matthias Preusser, Adelheid Woehrer, Wolfgang Sieghart, Sabine Strommer, Johannes Werzowa, Thorsten Fuereder, Volker Wacheck, Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biology & Therapy. ,vol. 7, pp. 1377- 1385 ,(2008) , 10.4161/CBT.7.9.6416
D. Forman, V.J. Burley, Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Practice & Research in Clinical Gastroenterology. ,vol. 20, pp. 633- 649 ,(2006) , 10.1016/J.BPG.2006.04.008
S. Kordes, A. Cats, S.L. Meijer, H.W.M. van Laarhoven, Targeted therapy for advanced esophagogastric adenocarcinoma Critical Reviews in Oncology Hematology. ,vol. 90, pp. 68- 76 ,(2014) , 10.1016/J.CRITREVONC.2013.10.004
David W Leung, George Cachianes, Wun-Jing Kuang, David V Goeddel, Napoleone Ferrara, None, Vascular endothelial growth factor is a secreted angiogenic mitogen Science. ,vol. 246, pp. 1306- 1309 ,(1989) , 10.1126/SCIENCE.2479986
Edmund Tischer, Denis Gospodarowicz, Richard Mitchell, Maria Silva, James Schilling, Kenneth Lau, Tracey Crisp, John C. Fiddes, Judith A. Abraham, Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family Biochemical and Biophysical Research Communications. ,vol. 165, pp. 1198- 1206 ,(1989) , 10.1016/0006-291X(89)92729-0
Hira Lal Goel, Arthur M. Mercurio, VEGF targets the tumour cell Nature Reviews Cancer. ,vol. 13, pp. 871- 882 ,(2013) , 10.1038/NRC3627
Taroh Satoh, Yasuhide Yamada, Kei Muro, Hidetoshi Hayashi, Yasuhiro Shimada, Daisuke Takahari, Keisei Taku, Takako Eguchi Nakajima, Xiaojin Shi, Kathryn H. Brown, Narikazu Boku, Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer Cancer Chemotherapy and Pharmacology. ,vol. 69, pp. 439- 446 ,(2012) , 10.1007/S00280-011-1723-8